Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    November 2017
  1. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Text format     Abstract available


  2. FORISSIER V, Tallet A, Cohen M, Classe JM, et al
    Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.
    Eur J Cancer. 2017;87:47-57.
    PubMed     Text format     Abstract available


  3. LE RHUN E, Bertrand N, Dumont A, Tresch E, et al
    Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Eur J Cancer. 2017 Nov 2. pii: S0959-8049(17)31346.
    PubMed     Text format     Abstract available


  4. DAROLES J, Borget I, Suciu V, Mazouni C, et al
    Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?
    Eur J Cancer. 2017;85:23-30.
    PubMed     Text format     Abstract available


  5. VAN DAM PA, Tomatis M, Marotti L, Heil J, et al
    Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.
    Eur J Cancer. 2017;85:15-22.
    PubMed     Text format     Abstract available


    October 2017
  6. PARK YH, Im SA, Kim SB, Sohn JH, et al
    Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Eur J Cancer. 2017;86:385-393.
    PubMed     Text format     Abstract available


  7. BIGANZOLI E, Desmedt C, Fornili M, de Azambuja E, et al
    Recurrence dynamics of breast cancer according to baseline body mass index.
    Eur J Cancer. 2017;87:10-20.
    PubMed     Text format     Abstract available


  8. VAN MAAREN MC, van Steenbeek CD, Pharoah PDP, Witteveen A, et al
    Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    Eur J Cancer. 2017;86:364-372.
    PubMed     Text format     Abstract available


  9. MULLOOLY M, Murphy J, Gierach GL, Walsh PM, et al
    Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.
    Eur J Cancer. 2017;86:326-333.
    PubMed     Text format     Abstract available


  10. TANG SS, Kaptanis S, Haddow JB, Mondani G, et al
    Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland.
    Eur J Cancer. 2017;84:315-324.
    PubMed     Text format     Abstract available


  11. STROM T, Harrison LB, Giuliano AR, Schell MJ, et al
    Tumour radiosensitivity is associated with immune activation in solid tumours.
    Eur J Cancer. 2017;84:304-314.
    PubMed     Text format     Abstract available


  12. DE NONNEVILLE A, Goncalves A, Zemmour C, Cohen M, et al
    Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    Eur J Cancer. 2017;84:34-43.
    PubMed     Text format     Abstract available


    September 2017
  13. PIVOT X, Verma S, Fallowfield L, Muller V, et al
    Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Eur J Cancer. 2017;86:82-90.
    PubMed     Text format     Abstract available


  14. BIGANZOLI L, Marotti L, Hart CD, Cataliotti L, et al
    Quality indicators in breast cancer care: An update from the EUSOMA working group.
    Eur J Cancer. 2017;86:59-81.
    PubMed     Text format     Abstract available


  15. GUERIN M, Rezai K, Isambert N, Campone M, et al
    PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Eur J Cancer. 2017;86:28-36.
    PubMed     Text format     Abstract available


  16. RAPHAEL J, Helou J, Pritchard KI, Naimark DM, et al
    Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Eur J Cancer. 2017;85:146-154.
    PubMed     Text format     Abstract available


  17. LOIBL S, de la Pena L, Nekljudova V, Zardavas D, et al
    Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Eur J Cancer. 2017;85:133-145.
    PubMed     Text format     Abstract available


  18. PHI XA, Houssami N, Hooning MJ, Riedl CC, et al
    Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
    Eur J Cancer. 2017;85:31-38.
    PubMed     Text format     Abstract available


  19. PULITI D, Bucchi L, Mancini S, Paci E, et al
    Corrigendum to "Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy" [Eur J Cancer 75 (April 2017) 109-116].
    Eur J Cancer. 2017 Sep 2. pii: S0959-8049(17)31218.
    PubMed     Text format    


  20. LIGHTOWLERS SV, Boersma LJ, Fourquet A, Kirova YM, et al
    Preoperative breast radiation therapy: Indications and perspectives.
    Eur J Cancer. 2017;82:184-192.
    PubMed     Text format     Abstract available


  21. MUCHOWICZ A, Wachowska M, Stachura J, Tonecka K, et al
    Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.
    Eur J Cancer. 2017;83:19-27.
    PubMed     Text format     Abstract available


  22. XIE ZM, Sun J, Hu ZY, Wu YP, et al
    Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy.
    Eur J Cancer. 2017;82:6-15.
    PubMed     Text format     Abstract available


    August 2017
  23. FREDHOLM H, Magnusson K, Lindstrom LS, Tobin NP, et al
    Breast cancer in young women and prognosis: How important are proliferation markers?
    Eur J Cancer. 2017;84:278-289.
    PubMed     Text format     Abstract available


  24. SCHREUDER K, Kuijer A, Rutgers EJT, Smorenburg CH, et al
    Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
    Eur J Cancer. 2017;84:270-277.
    PubMed     Text format     Abstract available


  25. FOCKE CM, Burger H, van Diest PJ, Finsterbusch K, et al
    Interlaboratory variability of Ki67 staining in breast cancer.
    Eur J Cancer. 2017;84:219-227.
    PubMed     Text format     Abstract available


  26. PETRELLI F, Ghidini M, Lonati V, Tomasello G, et al
    The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Eur J Cancer. 2017;84:141-148.
    PubMed     Text format     Abstract available


  27. SIMIN J, Tamimi R, Lagergren J, Adami HO, et al
    Menopausal hormone therapy and cancer risk: An overestimated risk?
    Eur J Cancer. 2017;84:60-68.
    PubMed     Text format     Abstract available


  28. VRIENS IJH, Keymeulen K, Lobbes MBI, van Bommel ACM, et al
    Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers.
    Eur J Cancer. 2017;81:74-80.
    PubMed     Text format     Abstract available


    July 2017
  29. KUMMEL S, Paepke S, Huober J, Schem C, et al
    Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
    Eur J Cancer. 2017;84:1-8.
    PubMed     Text format     Abstract available


  30. BARINOFF J, Schmidt M, Schneeweiss A, Schoenegg W, et al
    Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery.
    Eur J Cancer. 2017;83:116-124.
    PubMed     Text format     Abstract available


  31. DIMITROVA N, Znaor A, Agius D, Eser S, et al
    Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages.
    Eur J Cancer. 2017;83:43-55.
    PubMed     Text format     Abstract available


  32. BARTLETT JMS, Ahmed I, Regan MM, Sestak I, et al
    HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
    Eur J Cancer. 2017;79:129-138.
    PubMed     Text format     Abstract available


  33. ONEGA T, Weaver DL, Frederick PD, Allison KH, et al
    The diagnostic challenge of low-grade ductal carcinoma in situ.
    Eur J Cancer. 2017;80:39-47.
    PubMed     Text format     Abstract available


    June 2017
  34. SAGUATTI G, Naldoni C, Benelli E, Fedato C, et al
    Letter to the Editor regarding the paper by F. Cardoso et al. 'European Breast Cancer Conference manifesto on breast centres/units'.
    Eur J Cancer. 2017 Jun 26. pii: S0959-8049(17)31004.
    PubMed     Text format    


  35. HONG N, Yoon HG, Seo DH, Park S, et al
    Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Eur J Cancer. 2017;82:103-114.
    PubMed     Text format     Abstract available


  36. PIVOT X, Spano JP, Espie M, Cottu P, et al
    Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
    Eur J Cancer. 2017 Jun 22. pii: S0959-8049(17)30960.
    PubMed     Text format     Abstract available


  37. GLIGOROV J, Ataseven B, Verrill M, De Laurentiis M, et al
    Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
    Eur J Cancer. 2017 Jun 15. pii: S0959-8049(17)30961.
    PubMed     Text format     Abstract available


  38. PIVOT X, Fumoleau P, Pierga JY, Delaloge S, et al
    Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
    Eur J Cancer. 2017;81:151-160.
    PubMed     Text format     Abstract available


  39. BOERMAN LM, Maass SWMC, van der Meer P, Gietema JA, et al
    Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study.
    Eur J Cancer. 2017;81:56-65.
    PubMed     Text format     Abstract available


    May 2017
  40. LYNGE E, Beau AB, Christiansen P, von Euler-Chelpin M, et al
    Overdiagnosis in breast cancer screening: The impact of study design and calculations.
    Eur J Cancer. 2017;80:26-29.
    PubMed     Text format     Abstract available


  41. GILLON P, Touati N, Breton-Callu C, Slaets L, et al
    Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
    Eur J Cancer. 2017;79:226-234.
    PubMed     Text format     Abstract available


  42. KERBRAT P, Desmoulins I, Roca L, Levy C, et al
    Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
    Eur J Cancer. 2017;79:166-175.
    PubMed     Text format     Abstract available


  43. SCHRAA SJ, Frerichs KA, Agterof MJ, Hunting JCB, et al
    Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
    Eur J Cancer. 2017;79:152-157.
    PubMed     Text format     Abstract available


  44. SCHRODER J, Fietz T, Kohler A, Petersen V, et al
    Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
    Eur J Cancer. 2017;79:139-148.
    PubMed     Text format     Abstract available


  45. AALDERS KC, Kuijer A, Straver ME, Slaets L, et al
    Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Eur J Cancer. 2017;79:98-105.
    PubMed     Text format     Abstract available


    April 2017
  46. DEZELLUS A, Barriere P, Campone M, Lemanski C, et al
    Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Eur J Cancer. 2017;79:72-80.
    PubMed     Text format     Abstract available


  47. VAN NIJNATTEN TJA, Moossdorff M, de Munck L, Goorts B, et al
    TNM classification and the need for revision of pN3a breast cancer.
    Eur J Cancer. 2017;79:23-30.
    PubMed     Text format     Abstract available


  48. COLES CE, Fourquet A, Poortmans P
    Preoperative radiation therapy: The 'new' targeted breast cancer treatment?
    Eur J Cancer. 2017;78:116-117.
    PubMed     Text format    


  49. VAN ERKELENS A, Sie AS, Manders P, Visser A, et al
    Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.
    Eur J Cancer. 2017;78:45-52.
    PubMed     Text format     Abstract available


  50. ENGELHARDT EG, van den Broek AJ, Linn SC, Wishart GC, et al
    Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Eur J Cancer. 2017;78:37-44.
    PubMed     Text format     Abstract available


  51. MANNU GS, Dodwell D
    Making progress in early breast cancer: Taking time or accepting risk?
    Eur J Cancer. 2017;78:24-27.
    PubMed     Text format     Abstract available


  52. KOSMIN M, Makris A, Joshi PV, Ah-See ML, et al
    The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer.
    Eur J Cancer. 2017;77:109-116.
    PubMed     Text format     Abstract available


    March 2017
  53. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available


  54. NATORI A, Ethier JL, Amir E, Cescon DW, et al
    Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Eur J Cancer. 2017;77:40-47.
    PubMed     Text format     Abstract available


  55. VERMEULEN MA, Slaets L, Cardoso F, Giordano SH, et al
    Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Eur J Cancer. 2017 Mar 11. pii: S0959-8049(17)30726.
    PubMed     Text format     Abstract available


  56. GIACCHETTI S, Hamy AS, Delaloge S, Brain E, et al
    Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Eur J Cancer. 2017;75:323-332.
    PubMed     Text format     Abstract available


  57. RIET FG, Fayard F, Arriagada R, Santos MA, et al
    Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.
    Eur J Cancer. 2017;76:45-51.
    PubMed     Text format     Abstract available


  58. VAN RAMSHORST MS, van Werkhoven E, Mandjes IA, Schot M, et al
    Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
    Eur J Cancer. 2017;74:47-54.
    PubMed     Text format     Abstract available


  59. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available


    February 2017
  60. AMBATIPUDI S, Horvath S, Perrier F, Cuenin C, et al
    DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility.
    Eur J Cancer. 2017;75:299-307.
    PubMed     Text format     Abstract available


  61. DUFFY MJ, Harbeck N, Nap M, Molina R, et al
    Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Eur J Cancer. 2017;75:284-298.
    PubMed     Text format     Abstract available


  62. VAN KAMPEN RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, et al
    Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    Eur J Cancer. 2017 Feb 25. pii: S0959-8049(17)30088.
    PubMed     Text format     Abstract available


  63. YOUSSEF MM, Cameron D, Olsen S, Ferguson D, et al
    Does axillary lymph node dissection impact survival in patients with breast cancer and isolated tumour cells or micrometastasis in sentinel node?
    Eur J Cancer. 2017;75:167-168.
    PubMed     Text format    


  64. PULITI D, Bucchi L, Mancini S, Paci E, et al
    Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy.
    Eur J Cancer. 2017;75:109-116.
    PubMed     Text format     Abstract available


  65. MAKAMA M, Drukker CA, Rutgers EJ, Slaets L, et al
    An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint(R)).
    Eur J Cancer. 2017;75:5-13.
    PubMed     Text format     Abstract available


    January 2017
  66. FREOUR T, Barriere P, Masson D
    Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Eur J Cancer. 2017;74:1-8.
    PubMed     Text format     Abstract available


  67. CARDOSO F, Cataliotti L, Costa A, Knox S, et al
    European Breast Cancer Conference manifesto on breast centres/units.
    Eur J Cancer. 2017;72:244-250.
    PubMed     Text format     Abstract available


    December 2016
  68. GENRE L, Roche H, Varela L, Kanoun D, et al
    External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
    Eur J Cancer. 2016;72:200-209.
    PubMed     Text format     Abstract available


  69. TOUATI N, Tryfonidis K, Caramia F, Bonnefoi H, et al
    Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
    Eur J Cancer. 2016;72:95-102.
    PubMed     Text format     Abstract available


  70. LIU CY, Huang TT, Huang CT, Hu MH, et al
    EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
    Eur J Cancer. 2016;72:112-123.
    PubMed     Text format     Abstract available


  71. O'BRYAN S, Dong S, Mathis JM, Alahari SK, et al
    The roles of oncogenic miRNAs and their therapeutic importance in breast cancer.
    Eur J Cancer. 2016;72:1-11.
    PubMed     Text format     Abstract available


    November 2016
  72. SUTHERLAND S, Miles D, Makris A
    Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.
    Eur J Cancer. 2016 Nov 12. pii: S0959-8049(16)32450.
    PubMed     Text format     Abstract available


  73. MA Y, Zhang S, Zang L, Li J, et al
    Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Eur J Cancer. 2016;69:86-101.
    PubMed     Text format     Abstract available


  74. HEIL J, Schaefgen B, Sinn P, Richter H, et al
    Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
    Eur J Cancer. 2016;69:142-150.
    PubMed     Text format     Abstract available


  75. OULDAMER L, Bendifallah S, Chas M, Boivin L, et al
    Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
    Eur J Cancer. 2016;69:102-109.
    PubMed     Text format     Abstract available


  76. MILES D, Cameron D, Bondarenko I, Manzyuk L, et al
    Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Eur J Cancer. 2016 Nov 4. pii: S0959-8049(16)32470.
    PubMed     Text format     Abstract available


    October 2016
  77. JERZAK KJ, Pritchard KI
    The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?
    Eur J Cancer. 2016;68:173-175.
    PubMed     Text format    


    September 2016
  78. ABDEL-QADIR H, Amir E, Fischer HD, Fu L, et al
    The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Eur J Cancer. 2016;68:11-21.
    PubMed     Text format     Abstract available


  79. BOUDIN L, Chabannon C, Sfumato P, Sabatier R, et al
    Corrigendum to "Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation" [Eur J Cancer 57 (April 2016) 118-126].
    Eur J Cancer. 2016 Sep 24. pii: S0959-8049(16)32402.
    PubMed     Text format    


  80. KILLANDER F, Karlsson P, Anderson H, Mattsson J, et al
    No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
    Eur J Cancer. 2016;67:57-65.
    PubMed     Text format     Abstract available


    August 2016
  81. NAGRANI R, Mhatre S, Rajaraman P, Soerjomataram I, et al
    Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity.
    Eur J Cancer. 2016;66:153-161.
    PubMed     Text format     Abstract available


  82. ALBANELL J, Svedman C, Gligorov J, Holt SD, et al
    Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breas
    Eur J Cancer. 2016;66:104-113.
    PubMed     Text format     Abstract available


  83. TATE SC, Andre V, Enas N, Ribba B, et al
    Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
    Eur J Cancer. 2016;66:95-103.
    PubMed     Text format     Abstract available


  84. AMMITZBOLL G, Sogaard K, Karlsen RV, Tjonneland A, et al
    Physical activity and survival in breast cancer.
    Eur J Cancer. 2016;66:67-74.
    PubMed     Text format     Abstract available


    June 2016
  85. VON MINCKWITZ G, Rezai M, Tesch H, Huober J, et al
    Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
    Eur J Cancer. 2016;64:12-21.
    PubMed     Text format     Abstract available


  86. MARGUET S, Mazouni C, Ramaekers BL, Dunant A, et al
    European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Eur J Cancer. 2016;63:168-179.
    PubMed     Text format     Abstract available


  87. AALDERS KC, van Bommel AC, van Dalen T, Sonke GS, et al
    Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer.
    Eur J Cancer. 2016;63:118-126.
    PubMed     Text format     Abstract available


  88. IGNATIADIS M, Rack B, Rothe F, Riethdorf S, et al
    Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
    Eur J Cancer. 2016;63:97-104.
    PubMed     Text format     Abstract available


    May 2016
  89. JACKISCH C, Hegg R, Stroyakovskiy D, Ahn JS, et al
    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
    Eur J Cancer. 2016;62:62-75.
    PubMed     Text format     Abstract available


  90. SIA J, Moodie K, Bressel M, Lau E, et al
    A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment.
    Eur J Cancer. 2016;61:122-127.
    PubMed     Text format     Abstract available


  91. MACDONALD KV, Bombard Y, Deal K, Trudeau M, et al
    The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    Eur J Cancer. 2016;61:85-93.
    PubMed     Text format     Abstract available


  92. GOODWIN RA, Jamal R, Booth CM, Goss PE, et al
    Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
    Eur J Cancer. 2016;58:97-103.
    PubMed     Text format     Abstract available


  93. HOUVENAEGHEL G, Classe JM, Garbay JR, Giard S, et al
    Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Eur J Cancer. 2016;58:73-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: